Due to the continual emergence of new data, and the following guideline revisions, regarding the use of anti-CD38-based quadruplet regimens in the treatment of transplant ineligible newly diagnosed multiple myeloma (NDMM), clinicians need updated guidance on the data and best practices of these regimens. This enduring accredited activity will help hematologists and hematology-oncologists focus on improving in anti-CD38-based quadruplet regimens for NDMM. As a result of this microburst learning education, learners should be better able to: 1. Explain the role of anti-CD38 monoclonal antibody (mAB)-based quadruplet regimens in the treatment landscape for NDMM; 2. Review the latest clinical data of anti-CD38 mAB-based quadruplet regimens for transplant-ineligible patients with NDMM; and, 3. Analyze evidence-based strategies for optimizing outcomes with anti-CD38 mAB-based quadruplet regimens in patients with transplant-ineligible NDMM.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/BCK
- Start Date: 2025-02-26 06:00:00
- End Date: 2025-02-26 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Janssen (Any division) - Amount: 77593.0 - Is Kind Support: False Source: Sanofi - Amount: 100000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all